🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsSide Effects & ManagementAcid reflux/GERD worsening on GLP-1 — PPI interaction data

Acid reflux/GERD worsening on GLP-1 — PPI interaction data

Dr.GastroMayo Wed, May 27, 2026 at 7:16 PM 20 replies 733 viewsPage 1 of 4
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
May 27, 2026 at 7:16 PM#1

Read the primary source rather than the write-up and the two do not agree, so here is what is actually in it.

Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts. Receptor-level tachyphylaxis to the delayed-emptying effect develops over weeks while the central appetite effect persists, so the same dose is materially more comfortable at week six than at week two. A slower ladder therefore reaches the same dose with less cumulative nausea, not the same nausea spread thinner.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

What I am after is what distinguishes the nausea you can titrate through from the nausea that means stop. I would rather have one careful answer than five confident ones.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
4 24mike_nyc, VendorMark, COA_Karl and 1 other
Reply Quote Save Share Report
Dr.SurgeonPGH
Senior Member
1,345
6,789
Mar 2024
Pittsburgh, PA
May 27, 2026 at 7:32 PM#2
Dr.GastroMayo said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

Dr.GastroMayo has the substance of this right. The condition it depends on is worth stating. The line between titrate-through and stop is not severity, it is trajectory and what else is present. Nausea that peaks and improves within a week is the expected pattern. Nausea that is escalating, or that comes with severe upper-abdominal pain radiating to the back, or that prevents fluids for more than a day, is a different conversation and belongs with a clinician the same day.

That is the short version; the long version is somebody else's post.

3 23TomTeleRx, DoseLogDan, SleepFixSam
Reply Quote Save Share Report
DataDave
Senior Member
1,678
8,901
Apr 2024
Washington
Online
May 27, 2026 at 7:48 PM#3
Dr.GastroMayo said:
Holding genuinely reduces total burden rather than redistributing it, because the gastric-emptying component adapts.

I dislike how confidently this board tells people to push through. Incidence figures around 20 to 25% at the higher doses are class-typical, but the trials also had a discontinuation column, and "manageable with protocols" is not the same as manageable for everyone.

2 22LondonLisa, mike_nyc
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
NurseAsh_DET
Member
356
1,567
Sep 2024
Detroit, MI
May 27, 2026 at 8:04 PM#4

This one has a reasonably settled answer, so here it is. The practical protocol is dull and it works: smaller meals, stop eating at the first sign of fullness rather than at the end of the plate, drop the fat fraction of meals in the two days after dosing, and do not lie down straight after eating. Most of what people call unmanageable nausea is a meal-size and meal-composition problem interacting with a stomach that is emptying slowly.

Last edited: May 28, 2026 at 2:04 AM
1 21labquiet_amy
Reply Quote Save Share Report
wendy_avl
Member
245
1,123
Oct 2024
Asheville, NC
May 27, 2026 at 9:28 PM#5
Dr.SurgeonPGH said:
The line between titrate-through and stop is not severity, it is trajectory and what else is present.

Same pattern here, and in the same order.

Last edited: May 28, 2026 at 3:28 AM
50 20RickReta_CO, PharmHunterJen, TomTeleRx and 47 others
Reply Quote Save Share Report

Similar Threads

Nausea incidence by dose tier — STEP and SURMOUNT meta-analysis16 replies
Constipation on GLP-1: pathophysiology and fiber protocol5 replies
Alopecia on GLP-1 — telogen effluvium differential diagnosis3 replies
Gallbladder disease risk — cholelithiasis data from clinical trials12 replies
Pancreatitis risk assessment — pooled safety analysis15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register